0001437749-20-012488.txt : 20200604 0001437749-20-012488.hdr.sgml : 20200604 20200604171514 ACCESSION NUMBER: 0001437749-20-012488 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20200604 DATE AS OF CHANGE: 20200604 EFFECTIVENESS DATE: 20200604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CLEVELAND BIOLABS INC CENTRAL INDEX KEY: 0001318641 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 200077155 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-368344 FILM NUMBER: 20943703 BUSINESS ADDRESS: STREET 1: 73 HIGH STREET CITY: BUFFALO STATE: NY ZIP: 14203 BUSINESS PHONE: (716) 849-6810 MAIL ADDRESS: STREET 1: 73 HIGH STREET CITY: BUFFALO STATE: NY ZIP: 14203 D 1 primary_doc.xml X0708 D LIVE 0001318641 CLEVELAND BIOLABS INC 73 HIGH STREET Buffalo NY NEW YORK 14203 7168496810 DELAWARE None None Corporation true Christopher Zosh 73 High Street Buffalo NY NEW YORK 14203 Executive Officer Randy S. Saluck 73 High Street Buffalo NY NEW YORK 14203 Director Daniil Talyanskiy 73 High Street Buffalo NY NEW YORK 14203 Director Langdon Miller, MD 73 High Street Buffalo NY NEW YORK 14203 Executive Officer Andrei Gudkov, Ph.D., D., Sci. 73 High Street Buffalo NY NEW YORK 14203 Executive Officer Lea Verny 73 High Street Buffalo NY NEW YORK 14203 Director Alexander Andryushechkin 73 High Street Buffalo NY NEW YORK 14203 Director Anna Evdokimova 73 High Street Buffalo NY NEW YORK 14203 Director Ivan Fedyunin 73 High Street Buffalo NY NEW YORK 14203 Director Pharmaceuticals Decline to Disclose 06b false 2020-06-03 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 Park Avenue New York NY NEW YORK 10022 CA CALIFORNIA IL ILLINOIS NY NEW YORK 1588262 1588262 0 The offering amount includes the aggregate purchase and exercise price of the warrants. false 3 230188 0 In connection with a registered direct offering made concurrently with this placement, the issuer paid approximately $230,188 in placement agent fees and certain other compensation, as previously disclosed. 0 false CLEVELAND BIOLABS INC /s/ Christopher Zosh Christopher Zosh Vice President of Finance 2020-06-03